UPClytics
View all cases

UPC APP 17784/2025

EP4183412 Unitary patent · RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Case details
Status
Withdrawn
Action
Procedural application
Category
Withdrawal applications
Parties
Claimants
Representatives
Respondents
Representatives
Division
Milan CD
Technology
  • Chemistry
    Biotechnology · Pharmaceuticals
Language
—
First decided
Apr 22, 2025
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
Milan CDLocked
Judge Andrea PostiglioneLocked
Judge Anna-Lena KleinLocked
Judge Steen Wadskov-HansenLocked

At the UPC: Pfizer Group (31 cases)·GlaxoSmithKline Biologicals SA (20 cases)

This dispute contains 7 other proceedings

UPC CFI 476/2024·UPC CFI 468/2024·UPC APP 16306/2025·UPC APP 16366/2025·UPC APP 17607/2025 and 2 more

1 other defendants litigating the same or a related patent

UPC CFI 687/2024

Start a free trial to see how each one ended.

More cases: Milan CD·2025

Decisions
  • 2025-04-22
    Application RoP 265Public

    Summary: Order by Milan Central Division (UPC_CFI_687/2024, 22 April 2025) permitting Pfizer's withdrawal of the revocation action and counterclaim for revocation against GlaxoSmithKline's EP 4 183 412 (RSV F protein vaccine), and permitting GlaxoSmithKline to withdraw its patent amendment application. 60% court fee reimbursement was granted; each party bears its own costs.

    Show the legal issues (3)
    • Withdrawal of revocation action (R. 265 RoP)
    • Withdrawal of application to amend patent (R. 30, 49 RoP)
    • 60% court fee reimbursement
Documents
  • 952F7608FF32C4E96447972AD4129520_en.pdf2025-04-22EN